- The Korsch X3 is a state-of-the-art tablet press, custom-built to fit the site's needs.
- The press is equipped with full Band 5 containment, enabling the safe and contained manufacture of highly potent drug products at clinical and commercial scales.
- This positions Morpeth to support an increased demand for complex therapies.
MUMBAI, India, March 25, 2026 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), is proud to announce the installation of a Korsch X3 high containment tablet press at its integrated API and oral solid development and manufacturing site in Morpeth, UK. This acquisition marks a significant milestone as Morpeth celebrates its 20th anniversary, underscoring the facility's expertise and leadership in drug product manufacturing. Equipped with a specialized DryCon containment kit, the Korsch X3 is helping the site accelerate life-saving therapies to patients in need.
Photo - https://mma.prnewswire.com/media/2942423/Piramal_Pharma_Solutions_Morpeth_Korsch.jpg
Photo - https://mma.prnewswire.com/media/2942424/Peter_DeYoung_CEO_Piramal_Global_Pharma.jpg
Logo - https://mma.prnewswire.com/media/1726186/5883712/Piramal_Pharma_Solutions_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-solutions-commemorates-20th-anniversary-at-morpeth-facility-with-procurement-of-korsch-x3-tablet-press-302725276.html
